Aerie Pharmaceuticals Announces Public Offering of Common Stock
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/3/2026
- Wall St futures tepid as Middle East tensions keep investors wary
- Broadcom raises AI chip forecast as Big Tech keeps writing bigger checks
- Tesla to unveil Cybercab Texas today, details are few
- Snowflake soars 20% on earnings beat and raised guidance
- Oil prices hit fresh 6-week highs on renewed Middle East tensions
Aerie Pharma (AERI) Prices $75M Common Stock Offering at $53.75/Share; $50M in Common Stock Sold Through ATM Program
May 26, 2017 6:31 AM EDTAerie Pharmaceuticals, Inc. (NASDAQ: AERI), a clinical-stage pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with glaucoma and other diseases of the eye, today announced that it has priced its registered underwritten public offering (the Underwritten Offering) of $75 million of shares of its common stock at a price to the public of $53.75 per share. The offering was upsized by $25 million over the offering amount anticipated to be sold as previously announced.... More
